OBJECTIVES: Explore the impact of lowering Systolic Blood Pressure (SBP) on the Quality of Life (QoL) of Greek hypertensive patients undergoing pharmacotherapy and determine specific factors that contributed to the improvement of the patients' QoL during the period of treatment. METHODS: Data was derived from the PharmacoECOnomic Assessment of Prognostic Risk Occupational Survey (ECON-APROS). The ECON-APROS study was a cross-country prospective study that involved the 1-year monitoring of hypertensive patients undergoing pharmacotherapy, in terms of medical, economic and quality-of-life aspects. Out of total 1640 patient records collected, 1511 met the inclusion criteria of the study. Data regarding the patients' self reported QoL were collected at the initiation and at the termination of the 1-year period. Patients' self reported outcomes were based on a questionnaire combining generic and specific quality of life instruments. The statistical analysis was based on the logistic regression models in order to explore factors that influence patients' QoL. RESULTS: A total of 29.8% patients reported that their overall QoL has been improved during the 1-year period of treatment, while another 9.35% reported deterioration. Moreover, logistic regression showed that the decrease in the patients' SBP after 1 year of pharmacotherapy had a statistically significant influence in the improvement of the QoL (OR 1.021, 95%C.I. 1.012-1.030, p<0.0001) as opposed to the other variables inserted in the model (i.e. difference in the Diastolic Blood Pressure after 1 year of treatment, co-morbidity, BMI, age, sex, marital status, place of residence, private insurance, percentage of the patients' participation in drug costs). CONCLUSION: Lowering of the Systolic Blood Pressure during the course of anti-hypertensive treatment was shown to have a significant impact on the hypertensive patients' Quality of Life. The ECON-APROS is the first study to address such issues in the Greek healthcare setting and sets the foundations for further analysis.